CASI Pharmaceuticals (NASDAQ:CASI – Free Report) had its price target reduced by HC Wainwright from $12.00 to $6.00 in a research report report published on Wednesday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 […]